Aspira Pathlab & Diagnostics L
BSE: ASPIRA · Healthcare Service Provider · sector
Key numbers
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 31 companies in Healthcare Service Provider (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹2 cr vs borrowings ₹1 cr (FY26): cash is higher (net cash).
- Operating profit covered interest -0.2x in the last 12 months.
- Net loss in 3 of the last 6 quarters.
- No dividend in the last 5 financial years.
- Price ₹125.50 on 2026-10-26: -16.3% from the 52-week high, +156.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 6 | 5 | 8 | 5 | 7 | 6 |
| EBITDA | 1 | 1 | 2 | -1 | -0 | 0 |
| OPM % | 18.2% | 15.6% | 27.1% | -23.6% | -5.1% | 5.5% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 1 | 0 | 2 | -2 | -1 | -0 |
| EPS (₹) | 0.70 | 0.46 | 1.78 | 1.52 | 0.67 | 0.04 |
| Revenue YoY | +12.8% | +17.5% | ||||
| Profit YoY | -195.8% | -108.5% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 20 | 14 | 13 | 22 | 25 | 26 |
| EBITDA | 6 | 2 | -1 | 4 | 1 | 1 |
| Net profit | 4 | -0 | -3 | 2 | 0 | -0 |
| EPS (₹) | 4.33 | -0.09 | -2.60 | 2.01 | 0.05 | 4.01 |
| Revenue growth | -26.0% | -8.6% | +66.5% | +13.5% | – | |
| Profit growth | -102.0% | – | – | -97.6% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +20.0% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | +55.7% (2y) | +94.1% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 12 | 12 |
| Borrowings | 1 | 1 |
| Cash & equivalents | 2 | 2 |
| Total assets | 18 | 19 |
| Fixed assets | 4 | 4 |
| Capital work in progress | – | 0 |
| Investments | 0 | 0 |
| Receivables | 2 | 2 |
| Inventory | 1 | 1 |
| Payables | 1 | 1 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 2 | 1 |
| Cash from investing | 0 | -1 |
| Cash from financing | -1 | -1 |
| Capex | 0 | 1 |
| Free cash flow | 2 | 1 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 17.0% | 0.4% |
| ROCE % | 18.0% | 3.2% |
| Debtor days | 39 | 25 |
| Inventory days | 50 | 56 |
| Payable days | 73 | 92 |
| Cash conversion cycle (days) | 16 | -11 |
| Working capital days | 50 | 22 |
Peers in Healthcare Service Provider
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| LALPATHLAB | ₹31,100 cr | 57.2x | 12.4x | 23.1% | 29.6% | 27.9% | +11.1% | 0.71% |
| VIJAYA | ₹14,362 cr | 76.6x | 15.0x | 21.4% | 30.1% | 42.2% | +21.0% | 0.14% |
| METROPOLIS | ₹10,989 cr | 54.5x | 7.3x | 14.2% | 19.7% | 24.2% | +12.8% | 0.19% |
| THYROCARE | ₹7,491 cr | 42.6x | 12.8x | 31.1% | 39.7% | 31.4% | +16.3% | 1.99% |
| NEPHROPLUS | ₹6,095 cr | 71.6x | 5.5x | 6.9% | 13.4% | 22.7% | – | – |
| SURAKSHA | ₹1,628 cr | 45.4x | 6.7x | 15.7% | 25.2% | 31.4% | – | – |
| KRSNAA | ₹1,617 cr | 16.6x | 1.6x | 10.5% | 11.1% | 26.8% | +16.6% | 0.55% |
| 3BBLACKBIO | ₹1,193 cr | 21.2x | 3.7x | 18.7% | 22.8% | 34.9% | +127.8% | 0.29% |
| HEALTHX | ₹857 cr | – | 3.2x | -0.5% | – | – | – | – |
| ASPIRA | ₹129 cr | 31.3x | 10.6x | -3.7% | -0.5% | 3.8% | +20.0% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Healthcare Service Provider |
| Sub-industry | Healthcare Service Provider |
| Symbol | ASPIRA |
| BSE code | 540788 |
| ISIN | INE500C01017 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.